Cash-Generating Drugmakers: Defensive Momentum

Druck Drake’s thesis

The tech-led drawdown favors rotating toward established drugmakers whose shares are advancing on both monthly and quarterly horizons, rather than trying to catch falling AI infrastructure stocks. These businesses pair recurring prescription demand with positive free-cash-flow yields, providing a more defensive expression of confirmed momentum. With no confirmed monetary-policy tailwind in the supplied data, this is a relative-strength trade rather than a bet on Fed easing; deteriorating leaders